Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation.

ABSTRACT: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting up to six million people in the United States and more than 35 million individuals worldwide. Thromboembolism, including stroke, represents the most common AF-related morbidity and mortality and data indicate that anticoagulation can mitigate this risk by 65%. Our understanding of thromboembolism in AF, however, remains incomplete, and the mechanisms by which AF increases thromboembolic risk are areas of ongoing investigation and debate. Current guidelines do not differentiate between the frequency and duration of AF episodes (AF burden) when selecting which patients with AF should be treated with anticoagulation for thromboembolic risk reduction. Recent data, primarily using cardiac implantable electronic

SUBMITTER: Matos JD 

PROVIDER: S-EPMC7252665 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature